血友病A治療薬の世界市場：2019年～2023年

便利で新しいアプローチが市場成長を促進しています。世界の血友病A治療薬市場では、いくつかの新しい治療薬が登場しています。これらの治療薬は長期的な治療上のメリットをもたらし、そしてこの疾患を治療する可能性を持っているものもあります。 Technavioのアナリストは、世界の血友病A治療薬市場が2023年までに約7％のCAGRで成長すると予測しています。

当レポートでは、世界の血友病A治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

• 序文
• 序文
• 米ドルの通貨換算レート

第3章 市場状況

• 市場のエコシステム
• 市場の特徴
• 市場セグメンテーション分析

第4章 パイプライン分析

第5章 市場規模

• 市場の定義
• 市場規模（2018年）
• 市場規模および予測（2018年～2023年）

第6章 ファイブフォース分析

• バイヤーの交渉力
• サプライヤーの交渉力
• 新規参入の脅威
• 代替品の脅威
• 競争相手の脅威
• 市況

第7章 市場セグメンテーション：製品別

• 市場セグメンテーション：製品別
• 比較：製品別市場規模および予測（2018年～2023年）
• リコンビナント療法
• プラズマ誘導療法
• ホルモン療法
• その他
• 市場機会：製品別

第8章 顧客情勢

第9章 市場セグメンテーション：タイプ別

• オンデマンド治療
• 予防的治療
• インヒビター治療

第10章 地域別景観

• 地域別セグメンテーション
• 地域別比較：市場規模および予測（2018年～2023年）
• 南北アメリカ
• 欧州・中東・アフリカ地域
• アジア太平洋地域
• 主要国
• 市場機会

第11章 成長要因と課題

• 市場成長要因
• 市場の課題

第12章 市場動向

第13章 ベンダー情勢

• 概要
• 市場情勢の創造的破壊

第14章 ベンダー分析

• 対象ベンダー
• ベンダー分類
• ベンダーの市場ポジショニング
• Bayer
• CSL
• Novo Nordisk
• Pfizer
• Shire

第15章 付録

• 調査方法
• 略語のリスト

• Exhibit 01: Years in consideration
• Exhibit 02: Global rare disease market
• Exhibit 03: Segments of global rare disease market
• Exhibit 04: Market characteristics
• Exhibit 05: Market segments
• Exhibit 06: Pipeline molecules for hemophilia A
• Exhibit 07: Market definition - Inclusions and exclusions checklist
• Exhibit 08: Market size 2018
• Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
• Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
• Exhibit 11: Five forces analysis 2018
• Exhibit 12: Five forces analysis 2023
• Exhibit 13: Bargaining power of buyers
• Exhibit 14: Bargaining power of suppliers
• Exhibit 15: Threat of new entrants
• Exhibit 16: Threat of substitutes
• Exhibit 17: Threat of rivalry
• Exhibit 18: Market condition - Five forces 2018
• Exhibit 19: Product - Market share 2018-2023 (%)
• Exhibit 20: Comparison by product
• Exhibit 21: Recombinant therapies - Market size and forecast 2018-2023 ($ millions)
• Exhibit 22: Recombinant therapies - Year-over-year growth 2019-2023 (%)
• Exhibit 23: Plasma-derived therapies - Market size and forecast 2018-2023 ($ millions)
• Exhibit 24: Plasma-derived therapies - Year-over-year growth 2019-2023 (%)
• Exhibit 25: Hormonal therapies - Market size and forecast 2018-2023 ($ millions)
• Exhibit 26: Hormonal therapies - Year-over-year growth 2019-2023 (%)
• Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
• Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
• Exhibit 29: Market opportunity by product
• Exhibit 30: Customer landscape
• Exhibit 31: Market share by geography 2018-2023 (%)
• Exhibit 32: Geographic comparison
• Exhibit 33: Americas - Market size and forecast 2018-2023 ($ millions)
• Exhibit 34: Americas - Year-over-year growth 2019-2023 (%)
• Exhibit 35: EMEA - Market size and forecast 2018-2023 ($ millions)
• Exhibit 36: EMEA - Year-over-year growth 2019-2023 (%)
• Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
• Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
• Exhibit 39: Key leading countries
• Exhibit 40: Market opportunity
• Exhibit 41: Decision framework
• Exhibit 42: Manufacturer Co-Pay Programs
• Exhibit 43: Impact of drivers and challenges
• Exhibit 44: Vendor landscape
• Exhibit 45: Landscape disruption
• Exhibit 46: Vendors covered
• Exhibit 47: Vendor classification
• Exhibit 48: Market positioning of vendors
• Exhibit 49: Bayer - Vendor overview
• Exhibit 50: Bayer - Business segments
• Exhibit 51: Bayer - Organizational developments
• Exhibit 52: Bayer - Geographic focus
• Exhibit 53: Bayer - Segment focus
• Exhibit 54: Bayer - Key offerings
• Exhibit 55: CSL - Vendor overview
• Exhibit 56: CSL - Business segments
• Exhibit 57: CSL - Organizational developments
• Exhibit 58: CSL - Geographic focus
• Exhibit 59: CSL - Segment focus
• Exhibit 60: CSL - Key offerings
• Exhibit 61: Novo Nordisk - Vendor overview
• Exhibit 62: Novo Nordisk - Business segments
• Exhibit 63: Novo Nordisk - Organizational developments
• Exhibit 64: Novo Nordisk - Geographic focus
• Exhibit 65: Novo Nordisk - Segment focus
• Exhibit 66: Novo Nordisk - Key offerings
• Exhibit 67: Pfizer - Vendor overview
• Exhibit 68: Pfizer - Business segments
• Exhibit 69: Pfizer - Organizational developments
• Exhibit 70: Pfizer - Geographic focus
• Exhibit 71: Pfizer - Segment focus
• Exhibit 72: Pfizer - Key offerings
• Exhibit 73: Shire - Vendor overview
• Exhibit 74: Shire - Business segments
• Exhibit 75: Shire - Organizational developments
• Exhibit 76: Shire - Geographic focus
• Exhibit 77: Shire - Key offerings
• Exhibit 78: Validation techniques employed for market sizing
• Exhibit 79: List of abbreviations

About this market:

Emerging novel convenient approaches to drive market growth. Several novel therapies are emerging in the global hemophilia A therapeutics market. These therapies offer long lasting therapeutics benefits and some of the m possess potential to cure this disorder. Technavio's analysts have predicted that the hemophilia A therapeutics market will register a CAGR of almost 7% by 2023.

Market Overview:

Rising prevalence of hemophilia A

Hemophilia A is a rare genetic disorder, and the incidence of this disorder is gradually increasing. Hemophilia A accounts for about 80% of cases globally and mainly affects men.

High costs of hemophilia A therapeutics

High costs associated with drugs that treat hemophilia A are one of the biggest challenges faced by the market.

For the detailed list of factors that will drive and challenge the growth of the hemophilia A therapeutics market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Pfizer and Shire the competitive environment is quite intense. Factors such as the emerging novel convenient approaches and the rising prevalence of hemophilia A, will provide considerable growth opportunities to hemophilia A therapeutics manufactures. Bayer, CSL, Novo Nordisk, Pfizer, and Shire are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

• Market segmentation by product
• Comparison by product
• Recombinant therapies - Market size and forecast 2018-2023
• Plasma-derived therapies - Market size and forecast 2018-2023
• Hormonal therapies - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

• On demand treatment
• Prophylactic treatment
• Inhibitor treatment

PART 10: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 11: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 14: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer
• CSL
• Novo Nordisk
• Pfizer
• Shire

PART 15: APPENDIX

• Research methodology
• List of abbreviations